Science & Innovation
The MedRing as a platform is built upon market needs, medical science, high tech innovations and clinical studies.
The MedRing as a platform has been developed, tested and upgraded ever since 2016. Starting point was general knowledge about vaginal absorption of drugs, the positive results of the vaginal rings for contraconception and need for new reliable, personalized drug administration, made possible by emerging technology. Eventually, the platform offers great opportunities for innovative treatments, monitoring and insight for women’s health.
Following the first prototypes several tests and studies were executed by LiGalli in cooperation with renowned institutes like, CHDR, University of Leiden, Maxima Medical Center. This overview is carefully selected by LiGalli to give a clear view about the possibilities of the MedRing. It contains a small selection of our literature of important studies, articles and insights. If you are intrigued and would like to learn more, more please contact us.
The vaginal route
Why vaginal drug delivery?
Intra vaginal cavity and its high vasculation offers great possibilities for drug administering and diagnostics.
The vagina as a route for drug delivery: a review; Sushma Srikrishna & Linda Cardozo; Int Urogynecol J (2013) 24:537–543
The vaginal ring brings long term administration possibilities. As studied extensively with contraception rings the acceptance and usability of vaginal rings is good.
- Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world: Kathleen Ridgeway et al; Contraception 106 (2022) 16–33
Vaginal drug administering is safe and facilitates good absorption of the drug.
Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®); Devorah R Wieder Lynn Pattimakiel; International Journal of Women’s Health (2010) 2 401–409
- The vagina as a route for drug delivery: a review; Sushma Srikrishna & Linda Cardozo; Int Urogynecol J (2013) 24:537–543
The vaginal route for drug delivery brings high compliance, therapeutic plasma levels and less side effects.
Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®); Devorah R Wieder Lynn Pattimakiel; International Journal of Women’s Health (2010) 2 401–409
- The vagina as a route for drug delivery: a review; Sushma Srikrishna & Linda Cardozo; Int Urogynecol J (2013) 24:537–543
Bypass of the first pass effect allows for greater bioavailability, lower dosing with accompanying less side effects and less drug-drug interference.
Intra Vaginal Drug Delivery System: An Overview Chinmaya Keshari Sahoo et al; AJADD1 (2013) 043-055
- Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world: Kathleen Ridgeway et al; Contraception 106 (2022) 16–33
Vaginal ring
What is the performance of the MedRing?
The MedRing Controlled vaginal drug administration – First In Human study with Oxybutynin: therapeutic plasma levels combined with lower metabolites as compared to oral administration
- First-in human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring; Drugdelivery: Willem de Laat et al 2023
Get in touch
Office
Leiden Bio Science Park – BioPartner 1
Address
J.H. Oortweg 21
2333 CH Leiden
The Netherlands